We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
10 result(s) found, displaying 1 to 10
-
Oct-2023Prescription medicine evaluationActive ingredient: crisantaspase.
-
Designation or determinationOrphan drug
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VYXEOS daunorubicin (as hydrochloride) 44 mg and cytarabine 100 mg powder for injection vial.
-
Australian Public Assessment Report (AusPAR)New AusPAR for Vyxeos (daunorubicin and cytarabine) for the treatment of acute myeloid leukaemia.
-
Designation or determinationOrphan drug
-
Prescription medicine decision summaryTGA decision: VYXEOS (daunorubicin and cytarabine) is approved to treat therapy-related acute myeloid leukaemia and AML-MRC.
-
Prescription medicine registrationActive ingredients: daunorubicin hydrochloride, cytarabine.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EPIDYOLEX cannabidiol 100 mg/mL oral liquid solution bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DEFITELIO defibrotide 200 mg/2.5 mL concentrated solution for infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Sativex Oromucosal Spray, nabiximols 80 mg/mL pump actuated metered dose aerosol.